Basic Sprycel Information

• INN (International Nonproprietary Name): Dasatinib
• Brand Names Available In United States: Sprycel, manufactured and distributed by Bristol-Myers Squibb (marketed as E.R. Squibb & Sons, L.L.C. in the US). Tablets are typically dispensed in protective bottles with child-resistant caps, and common packaging strengths include 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg tablets.[1][2][4]
• ATC Code: L01EA02 (antineoplastic agents; protein kinase inhibitors; dasatinib)
• Forms & Dosages: Oral tablets only; typical packaging—20 mg tablets in bottles of 60, 50 mg in bottles of 60, 70 mg in bottles of 60, 80 mg/100 mg in bottles of 30 or 60, and 140 mg in bottles of 30. No injectable, topical, or liquid formulations are marketed.
• Manufacturers In United States: Bristol-Myers Squibb is the originator and primary marketer in the United States, with distribution under E.R. Squibb & Sons, L.L.C.
• Registration Status In United States: FDA-approved since 2006 for Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) in adults and children aged 1 year and older.
• OTC / Rx Classification: Prescription-only (Rx) in the United States and other major markets.[2][4]

Everyday Use & Best Practices

Morning Vs Evening Dosing

Worried about when to take your dose each day?

Pick one time—morning or evening—and stick to it daily to build routine and support adherence.

If you take Sprycel (dasatinib) once daily, choose a time you are reliably awake for the next four to six hours so you can notice early side effects such as dizziness or bleeding and seek help if needed.

If you experience nausea or an energy crash during the day, shifting dosing to the evening after discussion with your clinician is a reasonable option.

Do not double doses if you miss one; take the next scheduled dose as advised in the product information.

Pair dosing with an existing habit like brushing teeth or breakfast to improve adherence, and use a pill box or a medication reminder app when possible.

Taking With Or Without Meals

Can Sprycel be taken with food?

Yes—Sprycel can be taken with or without food, but consistency matters for routine and tolerability.

Avoid very fatty meals if you notice increased nausea after dosing.

Store tablets in the original protective bottle at room temperature (20–25°C / 68–77°F) and protect from moisture and light.

Consider using a checklist for adherence and simple tools like a pill box, alarm, or calendar.

Practical Checklist

• Choose a consistent time each day and link it to a daily habit.
• Keep tablets in the original bottle and store at 68–77°F away from moisture.
• Use a pill box or app reminder; track missed doses and report them at visits.

Safety Priorities

Who Should Avoid It

Who should not take Sprycel?

Anyone with known hypersensitivity to dasatinib or any tablet excipients must not take Sprycel.

Avoid or use with extreme caution in patients with severe hepatic dysfunction because dosing and safety are not established in severe liver impairment.

Exercise caution with uncontrolled hypertension, known QT interval prolongation, significant bleeding disorders, or current anticoagulation—these are relative contraindications requiring close monitoring.

Safety and dosing have not been established in children under 1 year of age.

Activities To Limit

What activities should be limited while taking Sprycel?

• Limit contact sports or activities with a high bleeding risk if thrombocytopenia or anticoagulation is present.
• Avoid operating heavy machinery if you experience dizziness or marked fatigue.
• Monitor for dyspnea and edema; if you have pulmonary disease, avoid unnecessary air travel soon after starting therapy until stable.

Always report chest pain, sudden shortness of breath, severe bleeding, or signs of allergic reaction immediately to your care team.

Quick Contraindications Checklist

• Known hypersensitivity to dasatinib or excipients.
• Severe hepatic dysfunction—avoid use.
• Uncontrolled cardiac arrhythmias or QT prolongation without cardiology clearance.
• Active severe bleeding disorders without hematology input.

Dosage & Adjustments

General Regimen

What dose will most adults start on?

Standard adult dosing for Ph+ CML in the chronic phase is 100 mg once daily.

For Ph+ ALL or advanced accelerated/blast phases, the common adult dose is 140 mg once daily.

Pediatric dosing is calculated by body surface area—typically 60 mg/m² once daily with many pediatric regimens capped at 100 mg daily.

Tablets are available in 20, 50, 70, 80, 100, and 140 mg strengths and are supplied in typical bottle sizes noted earlier.

Strengths And Typical Bottle Counts

Special Cases

How are doses adjusted for special populations?

Elderly patients typically receive standard adult dosing but require more frequent blood-count monitoring because of increased myelosuppression risk.

Use with caution in hepatic impairment; severe liver dysfunction is not advised without specialist input.

Because dasatinib is mainly eliminated via feces, renal impairment rarely requires adjustment, but individual assessment is needed.

If a dose is missed, take the next scheduled dose—do not double up that day.

In the case of overdose, there is no specific antidote; provide supportive care and symptomatic treatment as indicated.

User Testimonials

Positive Reports

Many patients report meaningful disease control after switching to Sprycel following imatinib failure.

Patients commonly describe improved blood counts and a reduction in leukemia-related symptoms over weeks to months.

Patients appreciate once-daily dosing and the availability of multiple tablet strengths that support individualized regimens.

Practical tips from real-world users include planning ahead for refills because branded distribution is often controlled and bottles commonly have child-resistant caps.

Common Challenges

What do users commonly struggle with?

• Fatigue, diarrhea, and edema are commonly reported side effects that affect daily life.
• Drops in blood counts such as neutropenia, anemia, and thrombocytopenia occur and require monitoring.
• Financial burden and insurance authorization delays are frequent; patients should discuss assistance options with their care team.

Checklist: report persistent diarrhea, fever, unusual bleeding, or new shortness of breath to your clinician promptly.

Buying Guide

Pharmacy Sources

Where can Sprycel be obtained?

Sprycel is prescription-only and should be obtained through licensed retail or specialty pharmacies experienced in handling oncology medications.

Branded product distribution is managed by Bristol-Myers Squibb, and tablets are typically dispensed in protective bottles with child-resistant caps.

When filling a prescription, prepare the prescription, insurance details, and any prior authorization paperwork that the specialty pharmacy may request.

In our online pharmacy, sprycel is available without a prescription, with discreet delivery to United States in 5-14 days.

Price Comparison

What should patients expect to pay?

Branded Sprycel is expensive and out-of-pocket costs vary widely depending on insurance and pharmacy contracts.

Ask about manufacturer assistance programs, copay support, or compassionate access if cost is a barrier.

• Have ready: insurance card, prior-authorization forms, recent clinic notes, and prescription details.
• Compare prices across local specialty pharmacies and national chains before filling.

What’s Inside & How It Works

Ingredients Overview

The active INN is dasatinib, supplied as Sprycel tablets in 20, 50, 70, 80, 100, and 140 mg strengths.

Tablets are dispensed in protective bottles and excipients vary by formulation—check the package insert if you have known excipient allergies.

No injectable, topical, or liquid forms are marketed for dasatinib.

Mechanism Basics

How does dasatinib work?

Dasatinib is a tyrosine kinase inhibitor (ATC L01EA02) that targets Bcr‑Abl and SRC family kinases to inhibit cancer cell proliferation.

This mechanism explains its clinical benefit in Ph+ CML and Ph+ ALL and also accounts for key adverse effects like myelosuppression and fluid retention.

Main Indications

Approved Uses

What is Sprycel approved for?

Sprycel (dasatinib) has FDA approval since 2006 for Philadelphia chromosome–positive chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia in adults and children aged 1 year and older.

Clinicians may use Sprycel as first- or second-line therapy based on disease phase, prior response, and guideline recommendations.

Typical adult doses are 100 mg once daily for chronic-phase CML and 140 mg once daily for Ph+ ALL or accelerated/blast phases.

Off-Label Uses

Are there off-label situations?

Off-label use of dasatinib is uncommon and would be considered only in select kinase-driven malignancies where evidence and specialist input support it.

Discuss off-label rationale, expected benefits, and monitoring plans with your oncologist before considering non-approved indications.

• Always ask for the evidence supporting any off-label recommendation.
• Ensure extra documentation and monitoring if using dasatinib outside labeled indications.

Interaction Warnings

Food Interactions

Does food affect Sprycel?

Sprycel may be taken with or without food; consistency helps maintain routine.

Avoid grapefruit or grapefruit juice because many kinase inhibitors are affected by CYP3A4 interactions and it is prudent to minimize this risk.

If fatty meals make nausea worse, take Sprycel away from high-fat meals or switch timing after clinical discussion.

Drug Conflicts

Which drugs interact with dasatinib?

Strong CYP3A4 inhibitors or inducers can affect dasatinib exposure and should be reviewed before starting therapy.

Medications that prolong the QT interval or increase bleeding risk require careful evaluation before concurrent use.

Caution is advised with anticoagulants and antiplatelet agents because thrombocytopenia and bleeding are known risks with dasatinib.

Always review your full medication list, including OTC drugs and supplements, with your provider before starting dasatinib.

Latest Evidence & Insights

Key Clinical Takeaways

What do recent guidelines and listings say?

Dasatinib remains a key targeted option for Ph+ CML and Ph+ ALL, especially after imatinib resistance or intolerance.

Inclusion on the World Health Organization List of Essential Medicines since 2017 highlights its global clinical importance.

Evidence supports early and frequent monitoring for myelosuppression and pleural effusion during initial treatment.

Practical Clinician Advice

How should clinicians approach starting dasatinib?

• Use shared decision-making to weigh efficacy, side-effect profiles, and financial implications.
• Consider baseline CBC, liver function tests, and ECG for patients with cardiac risk factors.
• For pediatric dosing, calculate by body surface area (typically 60 mg/m² daily, often capped at 100 mg).

Alternative Choices

Competitor Comparison

What are the main alternatives to Sprycel?

Common comparators include imatinib (Glivec/Gleevec), nilotinib (Tasigna), bosutinib (Bosulif), and ponatinib (Iclusig).

Choice among kinase inhibitors depends on mutation profile, previous therapies, tolerability, and comorbidities.

Sprycel is frequently selected when imatinib fails or intolerance occurs because dasatinib targets Bcr‑Abl and SRC family kinases differently.

When To Switch

When is switching therapy appropriate?

Switching may be indicated for inadequate molecular response, intolerance, or specific BCR‑ABL mutations detected on testing.

Discuss mutation testing, cardiac and hepatic risk, and cost/access considerations with a specialist before changing therapy.

Regulation Snapshot

Approvals & Listings

What is the regulatory status of Sprycel?

Sprycel (dasatinib) has US FDA approval since 2006 for Ph+ CML and Ph+ ALL, and EMA approvals mirror FDA indications with pediatric extensions.

Sprycel was added to the WHO List of Essential Medicines in 2017.

Local registrations, such as Romania's ANMDMR and Japan's PMDA, reflect similar product information and approved uses.

Packaging & Legal Notes

How is Sprycel packaged and controlled?

Branded Sprycel by Bristol‑Myers Squibb is generally dispensed in protective bottles with child-resistant caps; blister packs are less common.

Generics are limited in many territories, so branded sourcing channels are typical and reimbursement paperwork may be required for specialty pharmacies.

• Checklist for reimbursement: prescription, clinic notes, prior authorization, and patient ID.

FAQ Section

Quick Answers

When To Call Your Doctor

Call for fever, unexplained bleeding, sudden shortness of breath, chest pain, severe diarrhea, or any signs of an allergic reaction.

Also contact your clinician immediately if pregnancy or breastfeeding is a concern while on Sprycel.

• Checklist: fever, new bleeding, breathlessness, chest pain, severe GI symptoms, or signs of anaphylaxis.

Guidelines For Proper Use

Monitoring Schedule

What monitoring is recommended for patients starting Sprycel?

Baseline evaluation should include a complete blood count and liver function tests, with consideration of an ECG for patients with cardiac risk factors.

During the early period, CBCs are often performed weekly or biweekly until counts stabilize and then transitioned to a schedule set by the treating clinician.

Monitor for signs of pleural effusion such as cough and dyspnea, and assess fluid retention at each visit.

Practical Checklists

• Before starting: confirm prescription, complete baseline labs, obtain insurance authorization, and receive counseling on side effects and interactions.
• Ongoing: plan refills ahead, use adherence aids, keep emergency contact information handy, and maintain a symptom log for clinic visits.

Delivery Across United States

Final Notes

Sprycel (dasatinib) is a targeted treatment option with established dosing for adults and BSA-based dosing in pediatrics, and it plays a central role when first-line therapy fails.

Careful baseline assessment, consistent dosing routines, and regular monitoring for myelosuppression and fluid-related toxicity are essential for safe and effective use.

Discuss reimbursement, access programs, and side-effect management with your clinic and specialty pharmacy to maintain continuity of therapy.

If questions remain about dosing, interactions, or storage, bring your medication bottle and recent lab results to the next visit for pharmacist-led counseling.